Lupin unveils generic version of joint pain drug PENNSAID in US
Mumbai: Global pharma major Lupin Limited today announced the launch of authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics in the United States.
PENNSAID Topical Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of USD 509 million in the U.S. (IQVIA MAT October 2022).
Read also: Spiro Gavaris appointed as President of Lupin's US Generics Business
Medical Dialogues team had earlier reported that Lupin had received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP, 2% w/w to market a generic equivalent of Pennsaid Topical Solution, 2% w/w of Horizon Pharma Ireland DAC.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.